Maciej Ż.
- Country
- Poland
- Department
- #3861
Research Overview
- Effect of Orforglipron on Major Adverse Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
- Effect of Muvalaplin on Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: A Phase 3 Randomized Trial
- Inclisiran for Prevention of Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients with Atherosclerotic Cardiovascular Disease
Data & Insights
Has run more than one trial at 689 of 1182 partner sites.
Specializations
Cardiovascular Disease Management
This investigator specializes in the treatment and prevention of atherosclerotic cardiovascular disease (ASCVD), with particular emphasis on innovative therapeutic approaches for high-risk patients.
- Major Adverse Cardiovascular Events (MACE) Prevention
- Coronary Heart Disease Management
- Acute Limb Ischemia Treatment
Their research encompasses arterial revascularization procedures across coronary, cerebrovascular, and peripheral systems.
Lipid Management
The investigator focuses on advanced therapeutic strategies for hypercholesterolemia and lipid disorders, including novel approaches to LDL-cholesterol reduction.
- Lipoprotein Management
- Lipid-Lowering Therapies
- Cholesterol Target Achievement
Their work includes optimization of lipid-lowering treatments and evaluation of combination therapy approaches.
Preventive Cardiology
The investigator specializes in primary prevention of cardiovascular diseases, with particular attention to high-risk patient populations.
- Cardiovascular Risk Reduction
- Stroke Prevention
- Quality of Life Assessment
Their research extends to comprehensive cardiovascular risk management and preventive interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.